Platelet Aggregation and Interleukins Indicators Impacting the Outcomes of Ischemic Stroke

Relative assessment and relationship between of platelet aggregation and the level of interleukins IL-1β, IL-4, IL-6, and IL-18 among ischemic stroke (IS) patients.

A prospective clinical cohort study involved 108 IS patients, classified into group 1-surviving (93; 86.1%) and group 2-lethal outcomes (15; 13.9%). The studies were conducted in the most acute (first day of hospitalization) and acute (7 days of hospitalization) phases of IS. The level of interleukins was defined by enzyme immunoassay method. The platelet aggregation research was performed by the nephelometric method.

In the acute phase of the IS the first group, patients showed reduction in the level of IL-1β and IL-6, and increase in the level of IL-4, compared to the most acute period, whereas in patients of the second group further increase in IL-1β and IL-6, and reduction of IL-4 levels were recorded. Both in the most acute and acute phases of the IS, in parallel to the aggravation of platelet aggregation (PA) disturbances, the lethal outcome probability grew. The latter also grew together with increase in the synthesis of IL-1β and IL-6, in the most acute phase of the IS. In the acute phase of the IS, lethal outcome was recorded in all patients with high values of IL-1β and IL-6, and all patients with low values of IL-1β showed improvement.

Vivid disturbances of PA, IL-1β, IL-6, and IL-18 synthesis, in the most acute phase of the IS, signal higher probability of lethal outcome. Reduction in the levels of IL-1β, IL-6, and IL-18, and increase of IL-4 in the acute phase, means improvement in conditions.